Ratings by William Blair (Matt Phipps)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/15/2026 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
3.50 (2.13) |
-39.14% | Details | |
| 8/10/2026 | Tenax Therapeutics | TENX | Downgrade | Market Perform (Outperform) |
13.44 (1.36) |
-89.88% | Details | |
| 7/8/2026 | Zura Bio Ltd. | ZURA | New Coverage | Outperform (N/A) |
5.36 (3.88) |
-27.61% | Details | |
| 6/29/2026 | Evommune Inc | EVMN | Downgrade | Market Perform (Outperform) |
25.18 (5.17) |
-79.47% | Details | |
| 6/10/2026 | Cullinan Oncology Inc. | CGEM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2026 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2026 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2026 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2026 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/27/2026 | Autolus Therapeutics plc | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | Tenax Therapeutics | TENX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Jade Biosciences | JBIO | New Coverage | Outperform (N/A) |
14.05 (13.47) |
-4.13% | Details | |
| 3/5/2026 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2026 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
5.37 (0.86) |
-83.99% | Details | |
| 12/24/2025 | Dynavax Technologies | DVAX | Downgrade | Market Perform (Outperform) |
11.13 (15.50) |
39.26% | Details | |
| 12/1/2025 | Evommune Inc | EVMN | New Coverage | Outperform (N/A) |
20.71 (25.18) |
21.58% | Details | |
| 10/17/2025 | Kezer Life Sciences | KZR | Downgrade | Market Perform (Outperform) |
4.30 (7.29) |
69.53% | Details | |
| 10/16/2025 | Climb Bio | CLYM | New Coverage | Outperform (N/A) |
1.94 (9.82) |
406.19% | Details | |
| 9/29/2025 | Merus N.V. | MRUS | Downgrade | Market Perform (Outperform) |
68.89 (90.00) |
30.64% | Details | |
| 8/20/2025 | Insmed | INSM | New Coverage | Outperform (N/A) |
127.27 (96.27) |
-24.36% | Details | |
| 7/14/2025 | MiNK Therapeutics | INKT | Downgrade | Market Perform (Outperform) |
64.17 (9.41) |
-85.34% | Details | |
| 7/7/2025 | Jasper Therapeutics | JSPR | Downgrade | Market Perform (Outperform) |
6.77 (0.50) |
-92.61% | Details | |
| 6/30/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2025 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
9.70 (22.85) |
135.57% | Details | |
| 4/21/2025 | Context Therapeutics | CNTX | New Coverage | Outperform (N/A) |
0.84 (0.24) |
-71.43% | Details | |
| 3/11/2025 | Genmab A/S | GMAB | Upgrade | Outperform (Market Perform) |
24.14 (37.00) |
53.27% | Details | |
| 2/28/2025 | Kezer Life Sciences | KZR | Upgrade | Outperform (Market Perform) |
5.89 (4.30) |
-26.99% | Details | |
| 12/12/2024 | Keros Therapeutics | KROS | Downgrade | Market Perform (Outperform) |
68.65 (10.66) |
-84.47% | Details | |
| 12/3/2024 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2024 | Upstream Bio | UPB | New Coverage | Outperform (N/A) |
25.15 (2.76) |
-89.03% | Details | |
| 9/30/2024 | Tenax Therapeutics | TENX | New Coverage | Outperform (N/A) |
3.49 (13.44) |
285.1% | Details | |
| 8/30/2024 | NuCana | NCNA | Downgrade | Market Perform (Outperform) |
7.73 (0.99) |
-87.19% | Details | |
| 7/18/2024 | Agenus Inc. | AGEN | Downgrade | Market Perform (Outperform) |
17.73 (6.04) |
-65.93% | Details | |
| 5/3/2024 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
278.39 (432.49) |
55.35% | Details | |
| 4/15/2024 | Cullinan Oncology Inc. | CGEM | New Coverage | Outperform (N/A) |
17.37 (12.93) |
-25.56% | Details | |
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Market Perform (Outperform) |
52.97 (59.75) |
12.8% | Details | |
| 6/12/2023 | Chinook Therapeutics | KDNY | Downgrade | Market Perform (Outperform) |
23.99 (40.39) |
68.36% | Details | |
| 3/16/2023 | Kezer Life Sciences | KZR | Downgrade | Market Perform (Outperform) |
4.61 (7.29) |
58.13% | Details | |
| 11/14/2022 | Genmab A/S | GMAB | New Coverage | Market Perform (N/A) |
41.84 (24.14) |
-42.3% | Details | |
| 9/28/2022 | PhaseBio Pharmaceuticals Inc. | PHAS | Downgrade | Market Perform (Outperform) |
0.78 (0.07) |
-91.03% | Details | |
| 6/23/2022 | F-Star Therapeutics Inc. | FSTX | Downgrade | Market Perform (Outperform) |
3.98 (7.12) |
78.89% | Details | |
| 11/9/2021 | MiNK Therapeutics | INKT | New Coverage | Outperform (N/A) |
18.96 (9.41) |
-50.37% | Details | |
| 11/5/2021 | Calithera Biosciences | CALA | Downgrade | Market Perform (Outperform) |
1.90 (0.00) |
-100% | Details | |
| 10/21/2021 | Jasper Therapeutics | JSPR | New Coverage | Outperform (N/A) |
14.20 (6.77) |
-52.32% | Details | |
| 10/21/2021 | Tempest Therapeutics | TPST | New Coverage | Outperform (N/A) |
13.90 (0.62) |
-95.54% | Details | |
| 6/8/2021 | Biogen | BIIB | Upgrade | Outperform (Market Perform) |
395.85 (232.65) |
-41.23% | Details | |
| 4/8/2021 | F-Star Therapeutics Inc. | FSTX | New Coverage | Outperform (N/A) |
10.20 (7.12) |
-30.2% | Details | |
| 4/8/2021 | Merus N.V. | MRUS | New Coverage | Outperform (N/A) |
22.28 (68.89) |
209.2% | Details | |
| 11/9/2020 | Codiak Biosciences Inc. | CDAK | New Coverage | Outperform (N/A) |
9.09 (0.06) |
-99.34% | Details | |
| 7/21/2020 | Dynavax Technologies | DVAX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2020 | Portola Pharmaceuticals | PTLA | Downgrade | Market Perform (Outperform) |
7.76 (18.03) |
132.35% | Details | |
| 12/18/2019 | Aduro Biotech | ADRO | Downgrade | Market Perform (Outperform) |
1.15 (14.60) |
1169.57% | Details | |
| 9/16/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2019 | PhaseBio Pharmaceuticals Inc. | PHAS | New Coverage | Outperform (N/A) |
5.20 (0.07) |
-98.65% | Details | |
| 7/16/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Downgrade | Market Perform (Outperform) |
320.59 (395.85) |
23.48% | Details |
